KAIST Strikes Again: a New Nanoparticle Platform Turns Cancer Cells into Their Own Alarm System

KAIST has reported a new cancer-fighting nanoparticle platform that combines two powerful ideas into one system: helping the immune system notice cancer cells and delivering gene therapy directly into those cells. The basic concept is simple. Instead of only trying to poison or block a tumor from the outside, the nanoparticle makes the cancer cell send out a distress signal and at the same time carries therapeutic genetic material inside it.

Cancer cells are often good at hiding. They can avoid immune attack by disguising themselves or by turning down the signals that normally alert immune cells. That is one reason tumors can grow even when the immune system is active. The new platform is designed to push cancer cells into a state of severe internal stress, so they can no longer stay hidden.

The key feature is the particle’s helical shape. KAIST found that this shape matters as much as the chemical ingredients themselves. The particles also contain positively charged groups that help them interact with cell membranes. Together, the shape and charge allow the nanoparticle to enter cancer cells more effectively than similar particles without the helical structure. Once inside, it disrupts important internal structures, including mitochondria, which are essential for cell survival.

When a cancer cell is pushed into this kind of stress, it does not just die quietly. It releases danger signals that nearby immune cells can detect. Those signals act like an “I am here” message, telling the immune system that something abnormal is happening. This is called immunogenic cell death, and it is useful because the dying cancer cell helps recruit immune cells against the tumor itself.

The platform does more than trigger immune activation. It can also carry gene therapy cargo such as mRNA and siRNA. That means the same nanoparticle can be used both to wake up the immune system and to deliver a molecular treatment inside the cancer cell. To make this work, the researchers added a chemical group that helps the genetic cargo stick to the particle and remain more stable in the bloodstream.

In mouse studies, the system was loaded with siRNA designed to reduce PD-L1, a protein that tumors use to protect themselves from immune attack. The treatment reduced tumor growth substantially in models of melanoma and colorectal cancer, and it increased the presence of cytotoxic T cells inside the tumor. Those are the immune cells that directly kill cancer cells, so their increase is an encouraging sign.

Source.